Skip to main content
Premium Trial:

Request an Annual Quote

Mark Meyers, Mary Holland


EraGen Biosciences has hired Mark Meyers and Mary Holland as vice presidents of sales and marketing. In his new position, Meyers will build partnerships around EraGen’s Master Catalog platform, an interpretive proteomics system based on an evolutionary analysis of protein families. It can be used to determine model organisms and for drug target identification. Before joining EraGen, Meyers was vice president of sales for Scimagix.

Meantime, in her new position, Holland will be responsible for EraGen’s Aegis synthetic DNA platform. Before joining EraGen, Holland was the senior director of worldwide corporate accounts for Nanogen.

Filed under

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.